Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions rather than financial performance metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) following the notional re-investment of dividends paid on April 10, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the following transactions notified under Disclosure and Transparency Rule 3.1.4R(1)(c):
- Dr M M Slaoui: Connected person Dr K Slaoui received an increase of 85.217 ADSs at a price of $52.55 per ADS.
- Mr P C Thomson: Connected person Mrs K Thomson received an increase of 89.242 Ordinary Shares at a price of 1581.50 pence per Ordinary Share.
Notional dividends accrued will be paid out based on the percentage of holdings that vest after the relevant measurement period.
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares and ADSs held by the connected persons listed to assess total exposure.
- Review the dividend payment date of April 10, 2014, to ensure alignment with the company's broader dividend policy.